Quality Engineer 2

Draper has received up to $26.7 million from the Advanced Research Projects Agency for Health to develop computer models that predict drug safety and effectiveness. The award supports ARPA-H's CATALYST programme, which aims to create AI-powered models of human physiology to improve drug development. Draper will work with partners Revalia Bio, Yale University's Krishnaswamy Lab and LifeShare Network to build an integrated Human Data Stack. This system combines four layers of human data, including patient records, donated organ data, tissue biopsies and Draper's PREDICT96 system, which evaluates human cells under physiological conditions. The research will initially focus on human liver and kidney systems as proof of concept. The team aims to replace animal testing models and reduce drug development timelines from over 10 years to approximately five years.

Draper and partners awarded ARPA-H funding to develop new in silico models of Human physiology for drug development. February 24, 2026 CAMBRIDGE, Mass. - Draper recently received an up to $26.7 million other transaction award (OTA) from the Advanced Research Projects Agency for Health (ARPA-H). The award supports the agency's Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program, which will develop a new generation of in silico models of human physiology based on data from New Approach Methodologies (NAMs) to inform the drug development process. Draper's partners in the award are Revalia Bio, Inc., the Krishnaswamy Lab at Yale University, and LifeShare Network. Modern drug development and approval pathways need leading-edge methods for accurately predicting safety profiles. Leveraging artificial intelligence and machine learning, CATALYST intends to develop computer models that mimic real human biology to predict safety and effectiveness for Investigational New Drug (IND) candidates, ensuring that only the most promising and safest medicines move forward to patients. To overcome the limitations of existing human-based models, an integrated Human Data Stack will be developed utilizing four "layers" of human data that address different aspects of human biology. The four layers include patient data derived from Electronic Medical Records (EMR), macrophysiological data derived from donated human organs, detailed cellular and molecular level data from tissue and liquid biopsies, and microphysiological data from Draper's PREDICT96 system that evaluates functioning human cells in a complex multi-cellular environment under physiologic flow conditions. Data from the four layers will be used to feed continuous learning models that leverage state-of-the-art AI/ML techniques to support patient-specific absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) prediction. "Collectively, we believe an integrated Human Data Stack can be leveraged to develop a new class of Human Data Trial that can, in the near term, serve as a direct replacement to animal models under the current paradigm of drug development," said Greg Tietjen, CEO, Revalia Bio. "More importantly, data from the stack can directly inform the development of the next generation of in silico models that leverage the latest AI/ML capabilities to be continuously learning every time data is generated in any layer of the system. These predictive models can become drug-specific companion models that move with a drug through each stage of development and support pharmacovigilance efforts post FDA approval." "A unique aspect of the integrated Human Data Stack is the blending of static, end point data - patient and biopsy data - with two separate dynamic experimental systems - the macro- and microphysiological data. In these layers, dynamic human experiments can be run to rapidly test hypotheses and refine our in silico models without risk to living patients," added Tietjen. "As part of an integrated Human Data Stack, Draper's PREDICT96 system is able to provide a crucial layer of human data to support direct replacement of animal models, enabling faster and cheaper drug and medical countermeasure development," said Katie Hulse, Distinguished Member of the Technical Staff, Draper. Draper is a leader in microphysiological systems (MPS) used to model diseases and drug responses. In its 25-year history of MPS development, Draper has pioneered many groundbreaking advances, including long-term culture of mammalian cells in a microfluidic device, the first durable multi-organ system, the first multiplex instrumented MPS, and the first robust and reproducible operation of MPS in high containment. The proposal's research will use two specific human organ systems to provide proof of concept and lay a foundation for future expansion efforts. These organ systems are the human liver and kidney, the two primary filtering organs of the body that are susceptible to toxicity issues. Subsequent research, if funded, will involve using the in silico models developed in Phase 1 towards generating predictive ADME-Tox data for use in Investigational New Drug (IND) filings with the FDA. This research was, in part, funded by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the United States Government. About Draper. Draper is a non-profit research, development, and manufacturing company that solves some of the nation's most important challenges. With more than 2,500 employees working in collaboration across 12 locations, Draper delivers transformative, mission-driven solutions that successfully meet its customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend its legacy into the future, the Draper Scholars program engages with the next generation of innovators while DraperSPARX(TM) seeks to partner with startups and small businesses that can further its mission. To learn more about Draper, visit www.draper.com. About Revalia Bio. Revalia replaces animal models with scalable, AI-powered Human Data Trials built on living human organs - turning drug development into a high-velocity, data-driven engineering discipline, collapsing drug development from a 10+ year, $2B gamble into a <5-year, sub-$100M process. Learn more about Revalia Bio at https://www.revaliabio.com/. About Krishnaswamy Lab. Krishnaswamy Lab at Yale University develops data geometric, topological, dynamic, deep learning methods for analysis, visualization and representation of big data, especially biomedical data. Learn more about Krishnaswamy Lab at https://krishnaswamylab.org/. About LifeShare Network. At LifeShare Network, Inc, Draper Inc. believe in saving lives and inspiring hope. As a leading non-profit organization, its team fosters a strong commitment to serving donor heroes and their families. Draper Inc. ensure lifesaving gifts reach those in greatest need by collaborating with 159 hospitals in Oklahoma and transplant centers across the nation. Draper Inc. is at the forefront of transplant research, innovation and education, made possible by its three subsidiaries: LifeShare Innovations, LifeShare of Oklahoma, and LifeShare Tissue Services, Inc, which all exist from community support of the LifeShare Foundation. Released February 24, 2026

Draper receives $25 million in state and local funding for construction of its new IMPACT Center in Lowell. CAMBRIDGE, Mass., Oct. 27, 2025 /PRNewswire/ - Massachusetts Governor Maura Healey today announced up to $25 million in state and local funding in partnership with the City of Lowell to help fund the construction of Draper's Integrated Microelectronics Production & Advanced Chip Technology (IMPACT) Center in Lowell. The announcement is part of an initiative by the Healey-Driscoll Administration to more fully support the defense sector in the Commonwealth. The IMPACT Center will be a 75,000 square foot building located in the Lowell Innovation Network Corridor (LINC). The IMPACT Center will house advanced microelectronic design, production, and packaging facilities that will deliver cutting-edge technology to Draper's U.S. Military, Aerospace, and Government (USMAG) customers. Additionally, the Center will create more than 150 new highly skilled, classified national security jobs, including technicians, advanced degree engineers, and business executives. "Massachusetts is proud of our defense leadership - we are the birthplace of the National Guard, the U.S. Navy and the U.S. Coast Guard, and we've carried that legacy of innovation and service forward for generations," said Governor Maura Healey. "We are proud to support Draper's efforts to strengthen this leadership by establishing the IMPACT Center, which will create good jobs, grow our economy and bolster our national security in partnership with UMass Lowell and the City of Lowell." "Today's investment reflects Governor Healey's ongoing commitment to the needs of the nation's defense sector. The IMPACT Center will significantly expand the nation's secure, on-shore microelectronics production capacity and deliver new capabilities to our military," said Jerry Wohletz, Ph.D., President and CEO of Draper. "The facility will also strengthen the Commonwealth's manufacturing base and create new jobs for a highly skilled workforce, educated and trained in our local universities, colleges, and trade schools. We are grateful to the Healey-Driscoll Administration, the Commonwealth, and our partners in state and federal government for supporting our vision of what can be accomplished by this investment." The IMPACT Center is a key part of Draper's partnership with the University of Massachusetts Lowell (UML), the University of Massachusetts Building Authority, the City of Lowell, and the Commonwealth to bolster national security, drive economic growth, and position Massachusetts as a leader in advanced microelectronics manufacturing. Draper plans to provide up to $10 million in programming, research, and educational resources to UML over the coming decade. Earlier this year, Draper opened its newest corporate campus at UML as an anchor tenant in LINC. LINC is a 1.2 million square foot mixed use development set to foster a thriving innovation ecosystem that will transform the city's economic future. LINC is a public-private development project made possible by the leadership of the University of Massachusetts Lowell, the University of Massachusetts Building Authority (UMBA), and the City of Lowell, with significant support from the Commonwealth of Massachusetts. About Draper Draper is a non-profit research, development, and manufacturing company that solves some of the nation's most important challenges. With more than 2,500 employees working in collaboration across 12 locations, Draper delivers transformative, mission-driven solutions that successfully meet its customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend its legacy into the future, the Draper Scholars program engages with the next generation of innovators while DraperSPARX(TM) seeks to partner with startups and small businesses that can further its mission. To learn more about Draper, visit www.draper.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/draper-receives-25-million-in-state-and-local-funding-for-construction-of-its-new-impact-center-in-lowell-302595796.html SOURCE Draper Laboratory